Background: Preterm premature rupture of membranes is a challenging obstetric clinical scenario, since management requires
a careful balance between maternal wellbeing and tolerance for continuation of pregnancy and fetal wellbeing and maturity issues.
Aim: The influence and effect of non-β-lactam antibiotic administration on the expectant management course of PPROM as
regards the neonatal morbidity, mortality issues and maternal Additionally, infectious clinical outcomes.
Methodology: Research study subjects inclusive research criteria singleton, with no congenital fetal anomalies’ gestations
affected by Preterm premature rupture of membranes at or beyond 240/7 gestational weeks of gestation and delivery at less than
350/7 gestational weeks. 350 research study subjects were recruited for the research study categorized into two research groups
β- lactam and macrolide and non-β-lactam and macrolide research groups.
Results: Adjusted odds ratio of maternal and neonatal outcomes for women receiving a β-lactam and macrolide compared
with a non-β-lactam regimen showing statistical significance as regards bronchopulmonary dysplasia, endometritis (p value=0.012,
0.007 consecutively), whereas neonatal composite clinical outcome and chorioamnionitis didn’t show statistical significance (p
value=0.67,0.367).
Conclusion: Cases having preterm premature rupture of membranes that have been administered a β-lactam and macrolide
regimen are at lower risk to develop endometritis. Additionally, among neonates with PPROM the administration of a β-lactam
antibiotics doesn’t affect the neonatal morbidity rates.